Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians

References

• BarnesTRE1992Clinical assessment of the extrapyramidal side effects of antipsychotic drugsJ of Psychopharmacology621421
   PubMed Web of Science ®Google Scholar
• BasileVSMasellisMBadriF1999Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophreniaNeuropsychopharmacology21172710379516
   PubMed Web of Science ®Google Scholar
• BasileVSOzdemirVMasellisM2000A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophreniaMol Psychiatry54101710889552
   PubMed Web of Science ®Google Scholar
• BasileVSOzdemirVMasellisM2001Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophreniaMol Psychiatry6230411317228
   PubMed Web of Science ®Google Scholar
• BlasiGBertolinoA2006Imaging genomics and response to treatment with antipsychotics in schizophreniaNeuroRx31173016490418
   PubMedGoogle Scholar
• BradfordD2002CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendantsPharmacogenomics32294311972444
   PubMed Web of Science ®Google Scholar
• BrockmollerJKirchheinerJSchmiderJ2002The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatmentClinical Pharmacology and Therapeutics724385212386646
   PubMed Web of Science ®Google Scholar
• CaseyDE2004Pathophysiology of antipsychotic drug-induced movement disordersThe Journal of Clinical Psychiatry65 Suppl 925815189109
   PubMed Web of Science ®Google Scholar
• ChouWHYanFXde LeonJ2000Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illnessJ Clin Psychopharmacol202465110770465
   PubMed Web of Science ®Google Scholar
• ChouinardG2004New nomenclature for drug-induced movement disorders including tardive dyskinesiaThe Journal of Clinical Psychiatry65 Suppl 991515189106
   PubMed Web of Science ®Google Scholar
• DahlM-L2002Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?Clinical Pharmacokinetics414537012083975
   PubMed Web of Science ®Google Scholar
• de LeonJArmstrongSCCozzaKL2005The dosing of atypical antipsychoticsPsychosomatics462627315883149
   PubMed Web of Science ®Google Scholar
• de LeonJArmstrongSCCozzaKL2006Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19Psychosomatics4711216384802
   PubMed Web of Science ®Google Scholar
• de LeonJSusceMTMurray-CarmichaelE2006The amplichip CYP450 genotyping test-integrating a new clinical toolMol Diag Ther1013551
   PubMed Web of Science ®Google Scholar
• de LeonJSusceMTPanRM2005aThe CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuationJournal of Clinical Psychiatry66152715669884
   PubMed Web of Science ®Google Scholar
• de LeonJSusceMTPanRM2005bPolymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illnessJournal of Clinical Psychopharmacology254485616160620
   PubMed Web of Science ®Google Scholar
• del TaccaMLattanziLLastellaM2005Genotype A1/A2 associated with neuroleptic malignant syndromeBipolar Disorders7390116026494
   PubMed Web of Science ®Google Scholar
• DoradoPBereczRPenas-LledoEM2006Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugsCurrent Drug Targets716718017168842
   PubMed Web of Science ®Google Scholar
• EichhammerPAlbusMBorrmann-HassenbachM2000Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen’s study on DRD3 and tardive dyskinesiaAmerican Journal of Medical Genetics (Neuropsychiatric Genetics)961879110893495
   PubMed Web of Science ®Google Scholar
• EllingrodVLSchultzSKArndtS2000Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) scorePsychiatr Genet1091110909122
   PubMed Web of Science ®Google Scholar
• EllingrodVLSchultzSKArndtS2002Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6Pharmacotherapy2214161912432967
   PubMed Web of Science ®Google Scholar
• EllingrodVLPerryPJRingoldJC2005Weight gain associated with the -759 C/T polymorphism of the 5HT2C receptor and olanzapineAm J Med Genetics Part B (Neuropsychiatric Genetics)134B768
   PubMed Web of Science ®Google Scholar
• EllingrodVLBishopJRMolineJ2007Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophreniaPsychopharmacology Bulletin40576217285096
   PubMedGoogle Scholar
• FreudenreichOGoffDC2002Antipsychotic combination therapy in schizophrenia: A review of efficacy and risks of current combinationsActa Psychiatrica Scandinavica1063233012366465
   PubMed Web of Science ®Google Scholar
• Garcia-BarceloMMLamLCUngvariGS2001Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patientsJ Neural Transm108671711478419
   PubMed Web of Science ®Google Scholar
• GovTrack, us, HR. 493–110th Congress2007Genetic Information Nondiscrimination Act of 2007, GovTrack.us (database of federal legislation)Accessed Jul 12, 2007 URL: http://www.govtrack.us/congress/bill.xpd?bill=h110-493
   Google Scholar
• GuyW1976Abnormal involuntary movement scaleECDEU assessment manual for psychopharmacologyWashington, DCU.S. Public Health Service5347
   Google Scholar
• HaroJMSalvador-CarullaL2006The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for treatment of schizophreniaCNS Drugs2029330116599647
   PubMed Web of Science ®Google Scholar
• InadaTDobashiISugitaT1997Search for a susceptibility locus to tardive dyskinesiaHum Psychopharmacol Clin Exp12359
   Web of Science ®Google Scholar
• Ingelman-SundbergM2004Pharmacogenetics of cytochrome P450 and its applications in drug therapy, the past, present and futureTrends in Pharmacological Sciences2419320015063083
   PubMed Web of Science ®Google Scholar
• JanssenLPRisperdal^® prescribing information [online]Accessed 19 March 2007 URL: http://www.risperdal.com/active/janus/en_US/assets/common/company/pi/risperdal.pdf
   Google Scholar
• JeanneteauFFunalotBJankovicJ2006A functional variant of the dopamine D3 receptor is associated with risk and age at onset of essential tremorPNAS10310753816809426
   PubMed Web of Science ®Google Scholar
• JoyCBAdamsCELawrieSM2006Haloperidol versus placebo for schizophreniaCochrane Database of Systematic Reviews4CD003082
   Web of Science ®Google Scholar
• KaiserRTremblayP-BKlufmollerF2002Relationship between adverse effects of antipsychotic treatment and dopamine D[sub2] receptor polymorphisms in patients with schizophreniaMolecular Psychiatry769512192613
   PubMed Web of Science ®Google Scholar
• KapitanyTMeszarosKLenzingerE1998Genetic polymorphism for drug metabolism (CYP2D6) and tardive dyskinesia in schizophreniaSchizophr Res3210169713905
   PubMed Web of Science ®Google Scholar
• KapurSSeemanP2001Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?Am J Psychiatry158360911229973
   PubMed Web of Science ®Google Scholar
• KirchheinerJNickchenKBauerM2004Pharmacogenetics of anti-depressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responseMolecular Psychiatry94427315037866
   PubMed Web of Science ®Google Scholar
• KishidaIKawanishiCFurunoC2004Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D2 receptor geneMolecular Psychiatry9293815094790
   PubMed Web of Science ®Google Scholar
• LambertBLCunninghamFEMillerDR2006Diabetes risk associated with use of olanzapine, quetiapine and risperidone in veterans health administration patients with schizophreniaAmerican Journal of Epidemiology1646728116943266
   PubMed Web of Science ®Google Scholar
• LaneHYLeeCCLiuYC2005Pharmacogenetic studies of response to risperidone and other newer atypical antipsychoticsPharmacogenomics61394915882132
   PubMed Web of Science ®Google Scholar
• LererBSegmanRHFangerauH2002Pharmacogenetics of tardive dyskinesia. Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphismNeuropsychopharmacology271051912062911
   PubMed Web of Science ®Google Scholar
• LererBSegmanRHTanE-C2005Combined analysis of 635 patients confirms an age related association of serotonin 2A receptor gene with tardive dyskinesia and specificity for non-orofacial subtypeInternational Journal of Neuropsychopharmacology84112515857569
   PubMed Web of Science ®Google Scholar
• LererBSegmanRH2006Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementationDialogues in Clinical Neuroscience8859416640118
   PubMedGoogle Scholar
• LiebermanJAStroupTSMcEvoyJP2005Effectiveness of anti-psychotic drugs in patients with chronic schizophreniaN Engl J Med35312092316172203
   PubMed Web of Science ®Google Scholar
• LlerenaABereczRDoradoP2004QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrationsJournal of Psychopharmacology181899315260906
   PubMed Web of Science ®Google Scholar
• MalhotraAKMurphyGMJrKennedyJL2004Pharmacogenetics of psychotropic drug responseAm J Psychiatry1617809615121641
   PubMed Web of Science ®Google Scholar
• MiharaKKondoTSuzukiA2001No relationship between –141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary studyPsychiatry Research10133811223117
   PubMed Web of Science ®Google Scholar
• MiharaKKondoTSuzukiA2003Relationship between functional dopamine D2 and D3 receptors gene polymorphism and neuroleptic malignant syndromeAmerican Journal of Medical Genetics Neuropsychiatric Genetics1175760
   Web of Science ®Google Scholar
• MiharaKSuzukiAKondoT2001Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidolAmerican Journal of Medical Genetics (Neuropsychiatric Genetics)105271411353448
   PubMed Web of Science ®Google Scholar
• MillerDDEllingrodVLHolmanTL2005Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphismAmerican Journal of Medical Genetics Part B. Neuropsychiatric Genetics133B97100
   PubMed Web of Science ®Google Scholar
• MillerDDMcEvoyJPDavisS2005Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from CATIE schizophrenia trialSchizophrenia Research80334316171976
   PubMed Web of Science ®Google Scholar
• MorleyKIHallWD2004Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerationsJournal of Molecular Medicine82213014598045
   PubMed Web of Science ®Google Scholar
• MullerDJKennedyJL2006Genetics of antipsychotic treatment emergent weight gain in schizophreniaPharmacogenomics78638716981847
   PubMed Web of Science ®Google Scholar
• MurrayM2006Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agentsJournal of Pharmacy and Pharmacology588718516805946
   PubMed Web of Science ®Google Scholar
• NewcomerJW2006Medical risk in patients with bipolar disorder and schizophreniaJ Clin Psychiatry67 Suppl 9253016965186
   PubMed Web of Science ®Google Scholar
• OhmoriOSuzukiTKojimaH1998Tardive dyskinesia and debriso-quine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenicsSchizophr Res32107139713906
   PubMed Web of Science ®Google Scholar
• OlfsonMBlancoCLiuL2006National Trends in the outpatient treatment of children and adolescents with antipsychotic drugsArchives of General Psychiatry636798516754841
   PubMed Web of Science ®Google Scholar
• OlfsonMMarcusSCCorey-LisleP2006Hyperlipidemia following treatment with antipsychotic medicationsAm J Psychiatry1631821517012695
   PubMed Web of Science ®Google Scholar
• OzdemirVWilliams-JonesBCooperD2007Mapping translational research in personalized therapeuticsPharmacogenomics87785
   Web of Science ®Google Scholar
• RegenoldWTThaparRKMaranoC2002Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug useJournal of Affective Disorders70192612113916
   PubMed Web of Science ®Google Scholar
• ReynoldsGPTemplemanLAZhangZJ2005The role of 5-HT2C receptor in the pharmacogenetics of antipsychotic drug treatmentProgress in Neuro-Psychopharmacology and Biological Psychiatry291021815953671
   PubMed Web of Science ®Google Scholar
• ReynoldsGTemplemanLAGodlewskaBR2006Pharmacogenetics of schizophreniaExpert Opinion on Pharmacotherapy714294016859426
   PubMed Web of Science ®Google Scholar
• RietschelMKraussHMullerDJ2000Dopamine D3 receptor variant and tardive dyskinesiaEur Arch Psychiatry Clin Neurosci25031510738862
   PubMed Web of Science ®Google Scholar
• RyanMCCollinsPThakoreJH2003Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophreniaThe American Journal of Psychiatry160284912562574
   PubMed Web of Science ®Google Scholar
• SachseCBrockmollerJBaueS1997Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequencesAm J Hum Genet60284959012401
   PubMed Web of Science ®Google Scholar
• SchulzeTGSchumacherJMullerDJ2001Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophreniaAm J Med Genet10549850111496364
   PubMed Web of Science ®Google Scholar
• ScordoMGSpinaEFacciolàG1999Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidonePsychopharmacology147300610639689
   PubMed Web of Science ®Google Scholar
• SegmanRNeemanTHeresco-LevyU1999Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophreniaMol Psychiatry42475310395214
   PubMed Web of Science ®Google Scholar
• SegmanRHHeresco-LevyUFinkelB2001Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophreniaMol Psychiatry6225911317227
   PubMed Web of Science ®Google Scholar
• ShirzadiAAGhaemiSN2006Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndromeHarvard Review of Psychiatry141526416787887
   PubMed Web of Science ®Google Scholar
• SiposFRKehoePGBurnsT2006The cardiovascular and respiratory health of people with schizophreniaActa Psychiatrica Scandinavica113245616638069
   PubMed Web of Science ®Google Scholar
• SrivastavaVVarmaPGPrasadS2006Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV role of dopaminergic pathway gene polymorphismsPharmacogenetics and Genomics161111716424823
   PubMed Web of Science ®Google Scholar
• StahlSMGradyMM2004A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentationCurrent Medicinal Chemistry113132714965234
   PubMed Web of Science ®Google Scholar
• SteenVMLovlieRMacEwanT1997Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patientsMol Psychiatry2139459106238
   PubMed Web of Science ®Google Scholar
• SuzukiAKondoTOtaniK2001Association of the Taq1 polymorphism of the dopamine D2 receptor gene with predisposition to neuroleptic malignant syndromeAm J Psychiatry15817141611579007
   PubMed Web of Science ®Google Scholar
• Swainston-HarrisonTPerryCM2004Aripiprazole: a review of its use in schizophrenia and schizoaffective disorderDrugs6417153615257633
   PubMed Web of Science ®Google Scholar
• TanECChongSAMahendranR2001Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptorBiol Psychiatry50144711526996
   PubMed Web of Science ®Google Scholar
• TecottLHSunLMAkanaSF1995Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptorsNature37454267700379
   PubMed Web of Science ®Google Scholar
• TemplemanLAReynoldsGPArranzB2005Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosisPharmacogenetics and Genomics1519520015864111
   PubMedGoogle Scholar
• TiwariAKDesphandeSNRaoAR2005Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III Lack of association of CYP3A4 and CYP2D6 gene polymorphismsSchizophrenia Research7521615820320
   PubMed Web of Science ®Google Scholar
• Van BruntDLGibsonPJRamseyJL2003Outpatient use of major antipsychotic drugs in ambulatory care settings, Medgenmed [computer file]Medscape General Medicine516Accessed 15 August 2007 URL: http://www.medscape.com/viewarticle/45898414600653
   PubMedGoogle Scholar
• WilkaitisJMulvihillTNasrallahHASchatzbergAFNemeroffCB2004Classic antipsychotic medicationsAmerican psychiatric publishing textbook of psychopharmacology3rd edAmerican Psychiatric Publishing437
   Google Scholar
• WilkinsonGR2005Drug metabolism and variability among patients in drug responseN Engl J Med35221
   Web of Science ®Google Scholar
• Williams-JonesBOzdemirV2007Challenges for corporate ethics in marketing genetic tests. Journal of Business Ethics advance online publicationaccessed 7/12/07 http://www.springerlink.com/content/g6w320149833347h/?p=90f320134a9f4804b5bca7f6d3c3f60b&pi=0
   Google Scholar
• YoungRMLawfordBRBarnesM2004Prolactin levels in anti-psychotic treatment of patients with schizophrenia carrying the DRD2 alleleBritish Journal of Psychiatry1851475115286066
   PubMed Web of Science ®Google Scholar
• ZaiCCHwangRWDe LucaV2006Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patientsInternational Journal of Neuropsychopharmacology7113
   Google Scholar